VRTX - Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | Benzinga
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5, 2024.
Analysts expect the company to report quarterly earnings at $4.10 per share, up from year-ago earnings of $3.76 per share. The company is projected to post revenue of $2.51 billion for the latest quarter, compared to $2.3 billion in the year-earlier quarter, according to data from Benzinga Pro.
Vertex Pharmaceuticals recently announced results from its Phase 3 program (two Phase 3 trials) for the selective NaV1.8 inhibitor, VX-548, for moderate-to-severe acute pain.
Vertex Pharmaceuticals shares fell 2.1% to close at $424.68 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock ...